Electromed (ELMD) Oppenheimer 35th Annual Health Care MedTech and Services Conference summary

Company overview and market position

• Focuses on airway management with a single product, generating $60M in revenue and a $210M market cap.

• Manufactures in the US, with minimal tariff exposure and strong gross margins in the mid-70%.

• Profitable, cash-generating, and debt-free, with a direct-to-patient and provider model.

• Serves the bronchiectasis market, a chronic, underdiagnosed lung condition.

• 94% of revenue comes from home care patients, with about half from Medicare.

Market opportunity and growth drivers

• 824,000 US patients diagnosed with bronchiectasis, but only 127,000 use HFCWO technology.

• $2.3B market opportunity if all eligible patients are prescribed HFCWO.

• Additional 4.1M US patients have COPD-bronchiectasis overlap, representing further potential.

• Market growth supported by new drugs addressing inflammation and increased disease awareness.

• Company expects continued double-digit growth and expanding operating leverage.

Product features and patient impact

• SmartVest uses high-frequency chest wall oscillation to clear mucus, improving quality of life.

• Lightweight, comfortable, touchscreen-operated vest designed for adherence.

• Reimbursed by CMS and most private payers; not exposed to competitive bidding.

• High-touch patient support includes baseline and follow-up assessments, with documented outcomes.

• Use of SmartVest leads to 57% fewer antibiotic prescriptions, 59% fewer hospitalizations, and 75% fewer ED visits.